Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,605 total articles

Exodus Named UFC's First Official Payments Partner

Exodus Named UFC's First Official Payments Partner

Exodus Movement, Inc., a US-based fintech company specializing in self-custodial finance, announced a long-term partnership with UFC as its inaugural Official Payments Partner. The collaboration includes prominent branding at UFC events, integration into broadcasts, and innovative fan activations, with high visibility during the upcoming UFC Freedo…

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Corp. announced the successful completion of a GMP production run of its 5mg psilocybin capsules, currently prescribed for treatment-resistant depression in Australia. The company produced the capsules entirely in-house at its Health Canada-licensed facility, supporting both commercial patient access and upcoming clinical trials in th…

QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston

QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston

QTREX Quantum Ltd. announced its upcoming presentation at Quantum.Tech World 2026, showcasing its proprietary Additively Manufactured Electronics (AME) based monolithic connectivity components designed to address critical cryogenic interconnect challenges in superconducting quantum systems. The company emphasizes its advanced capabilities in scalab…

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri Inc., a biotech innovator with a patented 3D cell-expansion platform, announced that its subsidiary Cellav has completed the U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+. This milestone enables imminent U.S. commercial launch targeting the rapidly growing regenerative aesthetics market. Cli…

Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance

Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance

Aveanna Healthcare Holdings Inc. announced the completion of its acquisition of Family First Homecare, a multi-state pediatric home care provider, for $175.5 million cash funded by cash on hand. This acquisition expands Aveanna's specialized care offerings and geographic footprint. In conjunction with the acquisition, Aveanna updated its full-year …

Stardust Power Included in DOE-Funded Lithium Initiative

Stardust Power Included in DOE-Funded Lithium Initiative

Stardust Power Inc., a NASDAQ-listed U.S. lithium refinery developer, has been selected as an industrial partner in a Department of Energy-funded research project aimed at extracting lithium electrochemically from domestic waste streams such as wastewater and coal mine drainage. This collaboration supports the development of alternative domestic li…

FirstService Announces Amendment to Maximize Size of Normal Course Issuer Bid and Entering Into of Automatic Share Purchase Plan

FirstService Announces Amendment to Maximize Size of Normal Course Issuer Bid and Entering Into of Automatic Share Purchase Plan

FirstService Corporation has amended its normal course issuer bid (NCIB) to increase the maximum number of shares it can repurchase from 1.6 million to 4.1 million, representing up to 10% of its public float. The company also entered into an automatic share purchase plan (ASPP) with a designated broker to facilitate stock buybacks even during black…

Saia Provides April and May LTL Operating Data

Saia Provides April and May LTL Operating Data

Saia, Inc. disclosed increased Less-Than-Truckload (LTL) shipments and tonnage per workday for April and May 2026 compared to the same months in 2025, with shipment increases of 5.6% in April and 3.7% in May, and tonnage increases nearing 7-8% respectively. The data indicates improved freight activity and operational performance in the second quart…

XpressConnect™ PCIe® 6.0 and CXL 3.1 Retimers Address Latency and Signal‑Integrity Challenges in AI Data Centers

XpressConnect™ PCIe® 6.0 and CXL 3.1 Retimers Address Latency and Signal‑Integrity Challenges in AI Data Centers

Microchip Technology has introduced its XpressConnect PCIe 6.0 and CXL 3.1 retimers designed to extend signal reach and reduce latency in AI data centers. These retimers support higher bandwidth connectivity and lower pin-to-pin latency, enabling better utilization of GPUs and AI accelerators in large-scale AI workloads. Integrated with Microchip's…

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Pasithea Therapeutics announced that the FDA has granted Orphan Drug Designation to its drug candidate PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS). This designation supports the company's efforts in developing PAS-004 for ALS and potentially other MAPK pathway-related diseases, providing benefits such as tax credits, fee exemptions, an…

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics, a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced a virtual R&D Science Forum on June 16, 2026. The forum will feature expert speakers discussing the company's multi-asset gene therapy pipeline, including upcoming clinical trials targeting RDH12, MERTK, and RHO mutations, r…

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 at an increased dose of 10 mg/kg in their ongoing Phase 1/2 ELEVATE-45-201 clinical trial for ENTR-601-45, a potential treatment for Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping. Cohort 1 participants have mo…

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

BeyondSpring reported updated positive efficacy and safety results from its ongoing Phase 2 303 Study evaluating Plinabulin combined with pembrolizumab and docetaxel in metastatic non-small cell lung cancer patients who progressed after first-line immune checkpoint inhibitor therapy. The combination demonstrated favorable progression-free survival,…

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics announced alignment with the U.S. FDA on an earlier eGFR analysis for the ORIGIN Phase 3 trial of atacicept, a therapy targeting BAFF and APRIL for adults with IgA nephropathy (IgAN). The revised analysis is now planned for Q3 2026, ahead of the previous 2027 timeline. Pending positive results, the company plans to submit a supple…

Victoria’s Secret & Co. Reports First Quarter 2026 Results

Victoria’s Secret & Co. Reports First Quarter 2026 Results

Victoria's Secret & Co. delivered a robust first quarter 2026 performance, with net sales rising 15% to $1.56 billion, surpassing guidance. Operating income increased significantly to $76 million from $20 million a year prior, supported by strong sales growth across key brands and improved gross margins. The company raised its full-year 2026 net sa…

Telix and United Imaging Announce Strategic Theranostics Collaboration

Telix and United Imaging Announce Strategic Theranostics Collaboration

Telix Pharmaceuticals Limited (TLX) and United Imaging Healthcare North America have signed a Memorandum of Understanding to collaborate on the integration of Telix's molecular imaging products with United Imaging's advanced scanner platforms and AI capabilities. The initial focus will be on the US evaluation of TLX101-Px, a PET imaging candidate u…

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio has initiated dosing in its Phase 1 clinical trial for IBIO-600, a long-acting monoclonal antibody aimed at preserving muscle and improving body composition in adults with obesity. This milestone marks the company's transition to a clinical-stage biotech firm, showcasing progress in its AI-driven discovery platform and potential combination wi…